Based on the key indicators related to Aquestive Therapeutics' liquidity, profitability, solvency, and operating efficiency, Aquestive Therapeutics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Aquestive Therapeutics' Current Deferred Revenue is comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 16.2 M in 2025, despite the fact that Net Tangible Assets are likely to grow to (102.6 M). Key indicators impacting Aquestive Therapeutics' financial strength include:
Investors should never underestimate Aquestive Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Aquestive Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Aquestive Therapeutics.
Net Income
(46.34 Million)
Aquestive
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change To Inventory
Investments
Change In Cash
Net Borrowings
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
Change To Netincome
Change To Liabilities
End Period Cash Flow
Other Cashflows From Investing Activities
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Change Receivables
Stock Based Compensation
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Issuance Of Capital Stock
Dividends Paid
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Retained Earnings
Accounts Payable
Cash
Other Assets
Long Term Debt
Net Receivables
Inventory
Total Liab
Short Long Term Debt
Total Current Assets
Short Term Debt
Intangible Assets
Common Stock
Property Plant Equipment
Other Liab
Cash And Short Term Investments
Short Long Term Debt Total
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Non Current Assets Total
Non Currrent Assets Other
Common Stock Shares Outstanding
Long Term Debt Total
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Net Invested Capital
Net Working Capital
Common Stock Total Equity
Retained Earnings Total Equity
Capital Stock
Capital Lease Obligations
Non Current Liabilities Other
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Interest Income
Tax Provision
Net Interest Income
Depreciation And Amortization
Other Operating Expenses
Ebitda
Reconciled Depreciation
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past Aquestive Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aquestive Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Aquestive Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Aquestive Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aquestive Therapeutics. Check Aquestive Therapeutics' Beneish M Score to see the likelihood of Aquestive Therapeutics' management manipulating its earnings.
Aquestive Therapeutics Stock Summary
Aquestive Therapeutics competes with Evoke Pharma, Dynavax Technologies, Amphastar, Lantheus Holdings, and ANI Pharmaceuticals. Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey. Aquestive Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 157 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Aquestive Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Aquestive Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Aquestive Therapeutics's current stock value. Our valuation model uses many indicators to compare Aquestive Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aquestive Therapeutics competition to find correlations between indicators driving Aquestive Therapeutics's intrinsic value. More Info.
Aquestive Therapeutics is rated below average in return on asset category among its peers. It also is rated below average in profit margin category among its peers . At this time, Aquestive Therapeutics' Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aquestive Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Aquestive Therapeutics Systematic Risk
Aquestive Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aquestive Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Aquestive Therapeutics correlated with the market. If Beta is less than 0 Aquestive Therapeutics generally moves in the opposite direction as compared to the market. If Aquestive Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aquestive Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aquestive Therapeutics is generally in the same direction as the market. If Beta > 1 Aquestive Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Aquestive Therapeutics Thematic Clasifications
Aquestive Therapeutics is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
Today, most investors in Aquestive Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aquestive Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aquestive Therapeutics growth as a starting point in their analysis.
Aquestive Therapeutics March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Aquestive Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aquestive Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aquestive Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Aquestive Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aquestive Therapeutics's daily price indicators and compare them against related drivers.
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.